Development of a Vaccine for Human Parainfluenza Virus Type 1
Author Information
Author(s): Emmalene J Bartlett, Adam Castaño, Sonja R Surman, Peter L Collins, Mario H Skiadopoulos, Brian R Murphy
Primary Institution: National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
Hypothesis
Can recombinant live attenuated human parainfluenza virus type 1 (HPIV1) mutants serve as effective vaccine candidates?
Conclusion
The rHPIV1-CR84G/Δ170HNT553ALY942A and rHPIV1-CR84G/Δ170HNT553ALΔ1710–11 vaccine candidates are highly attenuated in African green monkeys and are planned for clinical trials.
Supporting Evidence
- The rHPIV1-CR84G/Δ170HNT553ALY942A vaccine candidate was protective against HPIV1 wt challenge.
- The rHPIV1-CR84G/Δ170HNT553ALΔ1710–11 vaccine candidate was not protective due to over-attenuation.
- Both vaccine candidates were highly attenuated in African green monkeys.
Takeaway
Scientists are trying to create a safe vaccine for a virus that makes kids sick, and they found two versions that work well in monkeys.
Methodology
The study involved creating recombinant HPIV1 mutants with specific mutations and testing their attenuation and immunogenicity in African green monkeys.
Limitations
The vaccine candidates may be over-attenuated, leading to low immunogenicity in the animal model used.
Participant Demographics
African green monkeys were used for testing the vaccine candidates.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website